Dendritic Cells & Their Role in Immunotherapy

Time: 3:00 pm
day: Day Two


• Presenting a new class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line)
• Discussing a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
• Understanding how the PDC*line is much more potent to prime and boost antitumour antigen, including neoantigens, specific cytotoxic T cells than conventional vaccines and improves the response to checkpoint inhibitors